NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB Co-infected Participants Examining Longitudinal Cytokine Profiles in HIV-TB Co-infected Participants to Study the Exit from Latent TB Infection and Death: A Supplemental Proposal for A5274

Study Location:

India

Topic:

Tuberculosis and HIV

IRB#:

IRB00091167

Enrollment:

Closed

Trial Period:

Ongoing

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following specific aims:

Specific Aims:

  1. To determine whether the levels of a panel of proinflammatory cytokines and IL-32 at baseline are associated with progression to TB disease in advanced HIV-infected persons
  2. To determine whether baseline levels of cytokines associated with IL-1 and type 1 interferons are associated with early mortality  
  3. To examine the association between longitudinal levels of the cytokines examined in aims 1 and 2  and development of TB or early mortality on ART 

Categories

Location
Topic

Clinical Trials

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled...

P1078 is a Phase IV, randomized, double-blind, placebo-controlled study of HIV-infected pregnant women and the infants born to...

Read More

P2001 (DAIDS ID 12026): Evaluating the Pharmacokinetics,...

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

Read More

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More

P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz...

Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years...

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More